| Sphingosine kinase 1 overexpression contributes to cetuximab resistance in human colorectal cancer models R Rosa, R Marciano, U Malapelle, L Formisano, L Nappi, C D'Amato, ... Clinical cancer research 19 (1), 138-147, 2013 | 117 | 2013 |
| Developing a highly specific biomarker for germ cell malignancies: plasma miR371 expression across the germ cell malignancy spectrum L Nappi, M Thi, A Lum, D Huntsman, BJ Eigl, C Martin, B O’Neil, ... Journal of clinical oncology 37 (33), 3090, 2019 | 106 | 2019 |
| The dual PI3K/mTOR inhibitor PKI-587 enhances sensitivity to cetuximab in EGFR-resistant human head and neck cancer models V D'amato, R Rosa, C D'amato, L Formisano, R Marciano, L Nappi, ... British journal of cancer 110 (12), 2887-2895, 2014 | 98 | 2014 |
| Epidermal growth factor-receptor activation modulates Src-dependent resistance to lapatinib in breast cancer models L Formisano, L Nappi, R Rosa, R Marciano, C D’Amato, V D’Amato, ... Breast Cancer Research 16, 1-15, 2014 | 78 | 2014 |
| LIN28B promotes the development of neuroendocrine prostate cancer J Lovnicki, Y Gan, T Feng, Y Li, N Xie, CH Ho, AR Lee, X Chen, L Nappi, ... The Journal of clinical investigation 130 (10), 5338-5348, 2020 | 72 | 2020 |
| Inhibition of Hedgehog signalling by NVP-LDE225 (Erismodegib) interferes with growth and invasion of human renal cell carcinoma cells C D’Amato, R Rosa, R Marciano, V D’Amato, L Formisano, L Nappi, ... British journal of cancer 111 (6), 1168-1179, 2014 | 62 | 2014 |
| Hsp27 inhibition with OGX-427 sensitizes non–small cell lung cancer cells to erlotinib and chemotherapy B Lelj-Garolla, M Kumano, E Beraldi, L Nappi, P Rocchi, DN Ionescu, ... Molecular cancer therapeutics 14 (5), 1107-1116, 2015 | 60 | 2015 |
| Ivermectin inhibits HSP27 and potentiates efficacy of oncogene targeting in tumor models L Nappi, AH Aguda, N Al Nakouzi, B Lelj-Garolla, E Beraldi, N Lallous, ... The Journal of clinical investigation 130 (2), 699-714, 2020 | 52 | 2020 |
| Integrated expression of circulating miR375 and miR371 to identify teratoma and active germ cell malignancy components in malignant germ cell tumors L Nappi, M Thi, N Adra, RJ Hamilton, R Leao, JM Lavoie, M Soleimani, ... European Urology 79 (1), 16-19, 2021 | 43 | 2021 |
| Plasma circulating tumor DNA and clonal hematopoiesis in metastatic renal cell carcinoma JVW Bacon, M Annala, M Soleimani, JM Lavoie, A So, ME Gleave, L Fazli, ... Clinical Genitourinary Cancer 18 (4), 322-331. e2, 2020 | 41 | 2020 |
| Clinical outcomes of perioperative chemotherapy in patients with locally advanced penile squamous-cell carcinoma: results of a multicenter analysis A Necchi, GR Pond, D Raggi, SR Ottenhof, RS Djajadiningrat, ... Clinical genitourinary cancer 15 (5), 548-555. e3, 2017 | 41 | 2017 |
| Clusterin knockdown sensitizes prostate cancer cells to taxane by modulating mitosis N Al Nakouzi, CK Wang, E Beraldi, W Jager, S Ettinger, L Fazli, L Nappi, ... EMBO molecular medicine 8 (7), 761-778, 2016 | 35 | 2016 |
| SEMS trial: Result of a prospective, multi-institutional phase II clinical trial of surgery in early metastatic seminoma. S Daneshmand, C Cary, TA Masterson, L Einhorn, SA Boorjian, ... Journal of Clinical Oncology 39 (6_suppl), 375-375, 2021 | 34 | 2021 |
| Surgery in early metastatic seminoma: a phase II trial of retroperitoneal lymph node dissection for testicular seminoma with limited retroperitoneal lymphadenopathy S Daneshmand, C Cary, T Masterson, L Einhorn, N Adra, SA Boorjian, ... Journal of Clinical Oncology 41 (16), 3009-3018, 2023 | 32 | 2023 |
| Increased anaerobic metabolism is a distinctive signature in a colorectal cancer cellular model of resistance to antiepidermal growth factor receptor antibody F Monteleone, R Rosa, M Vitale, C D'Ambrosio, M Succoio, L Formisano, ... Proteomics 13 (5), 866-877, 2013 | 30 | 2013 |
| MicroRNAs as biomarkers for germ cell tumors L Nappi, C Nichols Urologic Clinics 46 (3), 449-457, 2019 | 26 | 2019 |
| Prognostic and predictive factors in patients with advanced penile cancer receiving salvage (2nd or later line) systemic treatment: a retrospective, multi-center study C Buonerba, G Di Lorenzo, G Pond, G Carteni, S Scagliarini, A Rozzi, ... Frontiers in Pharmacology 7, 487, 2016 | 26 | 2016 |
| Angiogenic and signalling proteins correlate with sensitivity to sequential treatment in renal cell cancer R Rosa, V Damiano, L Nappi, L Formisano, F Massari, A Scarpa, ... British journal of cancer 109 (3), 686-693, 2013 | 23 | 2013 |
| Toll-like receptor 9 agonist IMO cooperates with everolimus in renal cell carcinoma by interfering with tumour growth and angiogenesis V Damiano, R Rosa, L Formisano, L Nappi, T Gelardi, R Marciano, ... British journal of cancer 108 (8), 1616-1623, 2013 | 23 | 2013 |
| Impact of COVID-19 outbreak on cancer immunotherapy in Italy: a survey of young oncologists M Ottaviano, M Curvietto, P Rescigno, M Tortora, G Palmieri, ... Journal for Immunotherapy of Cancer 8 (2), 2020 | 20 | 2020 |
